{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:22:31Z","timestamp":1787030551504,"version":"build-2736575974"},"reference-count":24,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2858","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:28:59Z","timestamp":1747286939000},"page":"1-7","source":"Crossref","is-referenced-by-count":5,"title":["Effect of anamorelin treatment duration on survival of patients with cancer cachexia: A retrospective study"],"prefix":"10.3892","volume":"23","author":[{"given":"Miyu","family":"Sasaya","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacy Assessment, Hoshi University, Tokyo 142\u20118501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takei","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Saitama Cancer Center, Ina, Saitama 362\u20110806, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Abe","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Saitama Cancer Center, Ina, Saitama 362\u20110806, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hiraide","sequence":"additional","affiliation":[{"name":"Department of Clinical Assessment, Tokyo University of Pharmacy and Life Sciences, Tokyo 192\u20110392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Torigoe","sequence":"additional","affiliation":[{"name":"Shonan University of Medical Sciences, Yokohama, Kanagawa 244\u20110806, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Saitama Cancer Center, Ina, Saitama 362\u20110806, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Saitama Cancer Center, Ina, Saitama 362\u20110806, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Sano","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacy Assessment, Hoshi University, Tokyo 142\u20118501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"key20250611134328_b1-MCO-23-1-02858","first-page":"155","article-title":"Cancer-induced cachexia: A guide for the oncologist","volume":"7","author":"Gullett","year":"2009","journal-title":"J Soc Integr Oncol"},{"key":"key20250611134328_b2-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: Understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"key20250611134328_b3-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"100092","key":"key20250611134328_b4-MCO-23-1-02858","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO clinical practice guidelines*","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"key":"key20250611134328_b5-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/s1359-6446(03)02826-5","article-title":"Catabolic mediators as targets for cancer cachexia","volume":"8","author":"Argil\u00e9s","year":"2003","journal-title":"Drug Discov Today"},{"key":"key20250611134328_b6-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/0-387-26283-0_9","article-title":"Cytokines as mediators and targets for cancer cachexia","volume":"130","author":"Argil\u00e9s","year":"2006","journal-title":"Cancer Treat Res"},{"key":"key20250611134328_b7-MCO-23-1-02858"},{"key":"key20250611134328_b8-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/CCO.0000000000000517","article-title":"Cancer cachexia, a clinical challenge","volume":"31","author":"Argil\u00e9s","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"key20250611134328_b9-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1254\/fpj.21046","article-title":"Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ\u00aeTablets), the first orally available drug for cancer cachexia with ghrelin-like action in Japan","volume":"156","author":"Nakanishi","year":"2021","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"key20250611134328_b10-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"key20250611134328_b11-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1210\/en.2003-1596","article-title":"Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein","volume":"145","author":"Chen","year":"2004","journal-title":"Endocrinology"},{"key":"key20250611134328_b12-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bjp.2008.153","article-title":"Regulation of muscle mass by growth hormone and IGF-I","volume":"154","author":"Velloso","year":"2008","journal-title":"Br J Pharmacol"},{"key":"key20250611134328_b13-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1161\/01.CIR.0000127956.43874.F2","article-title":"Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells","volume":"109","author":"Li","year":"2004","journal-title":"Circulation"},{"key":"key20250611134328_b14-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jcsm.12023","article-title":"Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved","volume":"6","author":"Chen","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key20250611134328_b15-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/SPC.0000000000000658","article-title":"Anamorelin in Japanese patients with cancer cachexia: An update","volume":"17","author":"Wakabayashi","year":"2023","journal-title":"Curr Opin Support Palliat Care"},{"key":"key20250611134328_b16-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/cncr.34154","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index","volume":"128","author":"Naito","year":"2022","journal-title":"Cancer"},{"key":"key20250611134328_b17-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jpainsymman.2015.09.010","article-title":"Validation of the modified Glasgow prognostic score in advanced cancer patients receiving palliative care","volume":"51","author":"de Paula Pantano","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"key20250611134328_b18-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"key20250611134328_b19-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2169\/internalmedicine.3577-24","article-title":"Efficacy of amamorelin in advanced pancreatic cancer patients with a poor performance status","volume":"64","author":"Takeda","year":"2025","journal-title":"Intern Med"},{"issue":"621","key":"key20250611134328_b20-MCO-23-1-02858","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08097-4","article-title":"Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia","volume":"31","author":"Tsukiyama","year":"2023","journal-title":"Support Care Cancer"},{"key":"key20250611134328_b21-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000433533","article-title":"The role of ghrelin in senescence: A mini-review","volume":"62","author":"Yin","year":"2016","journal-title":"Gerontology"},{"key":"key20250611134328_b22-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s10120-013-0300-8","article-title":"Clinical application of ghrelin administration for gastric cancer patients undergoing gastrectomy","volume":"17","author":"Takiguchi","year":"2014","journal-title":"Gastric Cancer"},{"key":"key20250611134328_b23-MCO-23-1-02858","doi-asserted-by":"publisher","first-page":"239","DOI":"10.7754\/Clin.Lab.2017.170804","article-title":"Low serum albumin correlates with poor survival in gastric cancer patients","volume":"64","author":"Ouyang","year":"2018","journal-title":"Clin Lab"},{"issue":"e7170","key":"key20250611134328_b24-MCO-23-1-02858","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7170","article-title":"Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan","volume":"13","author":"Takayama","year":"2024","journal-title":"Cancer Med"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:43:34Z","timestamp":1749624214000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,15]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2858","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}